argenx (NASDAQ:ARGX) Upgraded by Sanford C. Bernstein to “Outperform” Rating

Sanford C. Bernstein upgraded shares of argenx (NASDAQ:ARGX) from a market perform rating to an outperform rating in a research note released on Monday morning, Marketbeat Ratings reports.

ARGX has been the subject of several other research reports. Robert W. Baird increased their price objective on argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 4th. Oppenheimer increased their price objective on argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. William Blair reiterated an “outperform” rating on shares of argenx in a research report on Friday, February 28th. JMP Securities increased their price objective on argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research report on Tuesday, January 14th. Finally, Citigroup reiterated an “outperform” rating on shares of argenx in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, argenx presently has a consensus rating of “Moderate Buy” and an average price target of $687.00.

argenx Price Performance

argenx stock opened at $614.19 on Monday. argenx has a 12 month low of $349.86 and a 12 month high of $678.21. The business has a 50 day simple moving average of $637.58 and a 200-day simple moving average of $597.56. The stock has a market capitalization of $37.32 billion, a PE ratio of -697.94 and a beta of 0.59.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. As a group, equities research analysts anticipate that argenx will post 3.13 EPS for the current year.

Institutional Trading of argenx

A number of large investors have recently made changes to their positions in ARGX. GeoWealth Management LLC lifted its position in argenx by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock worth $31,000 after buying an additional 18 shares during the period. Whipplewood Advisors LLC purchased a new position in argenx during the fourth quarter worth about $37,000. Global Retirement Partners LLC lifted its position in argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after buying an additional 48 shares during the period. FIL Ltd purchased a new position in argenx during the fourth quarter worth about $38,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in argenx during the fourth quarter worth about $38,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.